Cartesian Therapeutics, Inc. (RNAC)
Oxford Ledge is still expanding full research coverage of RNAC. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Cartesian Therapeutics develops mRNA-based cell therapies for autoimmune diseases as an outpatient alternative to existing biologic and DNA-based treatments.
SEC filings
- 8-K Shareholder vote results 2026-06-17
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-06-09
- 8-K Entry into material agreement; Creation of direct financial obligation; 3.02; Departure/election of directors or officers; Regulation FD disclosure; Financial statements and exhibits 2026-05-26
- 10-Q Quarterly financial report (unaudited) 2026-04-30
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-04-30
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for RNAC. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open RNAC in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.